Mitsubishi Tanabe Incurs Operating Loss 2 Years Running as Parkinson’s Write-Down Weighs

Mitsubishi Tanabe Pharma booked a group operating loss for the second consecutive year in FY2020 as a delay in Israeli subsidiary NeuroDerm’s Parkinson’s project ND0612 resulted in an impairment loss of nearly 85 billion yen. In the year through March...read more